Get the Stockscreener App
51.74
1.63%
0.83
After Hours:
52.08
0.34
+0.66%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $51.74, with a volume of 12.61M.
It is up +1.63% in the last 24 hours and up +3.58% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
See More
Previous Close:
$50.91
Open:
$51.51
24h Volume:
12.61M
Relative Volume:
0.97
Market Cap:
$103.21B
Revenue:
$46.51B
Net Income/Loss:
$-6.54B
P/E Ratio:
13.13
EPS:
3.94
Net Cash Flow:
$12.95B
1W Performance:
+3.46%
1M Performance:
+3.58%
6M Performance:
-4.59%
1Y Performance:
-10.85%
1-Day Range:
$51.03
$51.94
1-Week Range:
$49.11
$52.16
52-Week Range:
$39.35
$58.06
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday - The Motley Fool
Market Today: GM Faces NHTSA Action, Bristol Myers Wins Court Ca - GuruFocus.com
Prime’s $3.61B Bristol Myers deal is year’s fourth largest - BioWorld Online
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug - MSN
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug - Reuters
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug - The Denver Gazette
Bristol Myers Beats $6.4 Billion Lawsuit Over Delayed Cancer Drug - U.S. News & World Report
Analysts Think There's Still Time To Get In On Edgewise - Benzinga
Bristol Myers Squibb Marks 10 Years of Global Patient Week with Community Initiatives in the Region - The Malaysian Reserve
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - AOL
Prime to narrow gene editing research as it strikes deal with Bristol Myers - BioPharma Dive
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - Yahoo Finance
Prime Medicine Unveils Strategically Focused Pipeline - GlobeNewswire Inc.
Mackenzie Financial Corp Sells 77,522 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Marshall Wace LLP Has $10.62 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb stock backed by Goldman Sachs as Cobenfy's unique safety profile sets it apart - Investing.com South Africa
Bristol-Myers Squibb stock backed by Goldman Sachs as Cobenfy's unique safety profile sets it apart - Investing.com Australia
Bristol-Myers stock gets price target boost on COBENFY approval - Investing.com
3 Surprisingly Underrated Stocks to Buy Right Now - The Motley Fool
Public Sector Pension Investment Board Has $3.24 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb Co (BMY) Stock Price, Trades & News - GuruFocus.com
FDA approves Bristol Myers Squibb’s Cobenfy - Indian Pharma Post
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, and More - MSN
Bristol-Myers Squibb Target of Unusually Large Options Trading (NYSE:BMY) - MarketBeat
Bristol Myers, Costco, EchoStar, DJT, Wynn, HP Inc., and More Stock Movers - Barron's
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential - Benzinga
Bristol-Myers Squibb Co (BMY) Trading 2.99% Higher on Sep 27 - GuruFocus.com
Bristol's Growing Portfolio and Pipeline Partly Offset Headwinds From Generic Competition - Morningstar
BMS wins approval for schizophrenia drug acquired from Karuna - Pharmaceutical Technology
Pharma Stock Rises on Cleared Schizophrenia Treatment - Schaeffers Research
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting - StockTitan
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment - Nasdaq
Bristol Myers wins US FDA approval for new type of schizophrenia drug - Reuters
Bristol Myers Squibb shares move higher on FDA approval of schizophrenia drug - Proactive Investors USA
Bristol-Myers Squibb stock gains on FDA approval of schizophrenia treatment - Investing.com
Costco dips premarket; Bristol-Myers Squibb, Wynn Resorts rise - Investing.com
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades - Benzinga
Wall Street On Wait-And-Watch Mode Ahead Of Inflation Data, Bitcoin Holds Above 65.5K: Analyst Says Volatility Ahead Providing Better Entry Point Into Long-term Bull Market - Benzinga
Wall Street Breakfast Podcast: Bristol-Myers Wins FDA Nod - Seeking Alpha
Bristol Myers Squibb shares move higher on FDA approval of schizophrenia drug - Proactive Investors Australia
Bristol Myers: FDA approval in schizophrenia - Marketscreener.com
Bristol Myers gets FDA approval for Cobenfy to treat Schizophrenia - The Times of India
US FDA approves Bristol Myers' Squibb drug for treating schizophrenia - Business Standard
Bristol Myers Squibb : Investor Overview - Marketscreener.com
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults - StockTitan
U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults - Quantisnow
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia Drug Type in Decades - Bloomberg
Bristol Myers Gets US Nod for First New Schizophrenia Drug Type in Decades - Bloomberg
FDA approves schizophrenia drug that could alter how disorder is treated - STAT
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bristol Myers Squibb Co Stock (BMY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gallman Cari | EVP, Corporate Affairs |
Aug 01 '24 |
Option Exercise |
0.00 |
1,061 |
0 |
2,493 |
| Shanahan Karin | EVP, Glob. Prod. Dev. & Supply |
Apr 01 '24 |
Option Exercise |
0.00 |
3,306 |
0 |
6,532 |
| Lenkowsky Adam | EVP, Chief Commercial Officer |
Mar 10 '24 |
Option Exercise |
0.00 |
15,016 |
0 |
13,859 |
| LEUNG SANDRA | EVP, General Counsel |
Mar 10 '24 |
Option Exercise |
0.00 |
46,784 |
0 |
371,312 |
| Plenge Robert M | EVP, Chief Research Officer |
Mar 10 '24 |
Option Exercise |
0.00 |
9,143 |
0 |
15,182 |
| Poole Ahn Amanda | EVP, Chief Human Resources |
Mar 10 '24 |
Option Exercise |
0.00 |
5,458 |
0 |
4,841 |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. |
Mar 10 '24 |
Option Exercise |
0.00 |
38,388 |
0 |
80,256 |
| Holzer Phil M | SVP and Controller |
Mar 10 '24 |
Option Exercise |
0.00 |
5,520 |
0 |
14,916 |
| Hoch Lynelle | President, Cell Therapy Org. |
Mar 10 '24 |
Option Exercise |
0.00 |
4,351 |
0 |
3,781 |
| Gallman Cari | EVP, Corporate Affairs |
Mar 10 '24 |
Option Exercise |
0.00 |
2,761 |
0 |
2,655 |
0.28%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):